Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 4 of 4 for “"Ibrutinib"”.
-
QUANTITATIVE PROTEOMIC APPROACHES TO STUDY DRUG MECHANISM OF ACTION
… order to study covalent mechanism of action of ibrutinib, a covalent inhibitor of the tyrosine protein kinase BTK, approved by FDA in 2013 for the treatment of B cell malignancies. We used ibrutinib as case study, but the developed protocols can be applied to the study of other covalent …
-
Novel approaches to assess cellular interactions and their role in the pathology and treatment of lymphoproliferative disorders
… quantitatively described. Inhibition of BTK by ibrutinib resulted in uniform populations of globular cells with retained polarity and, consequently, increased amoeboid motility. BTK blockage is recognised to impair integrin-mediated retention of leukaemic cells within tissue niches, leading to …
-
The role of type I interferon in chronic lymphocytic leukemia
… bruton’s tyrosine kinase inhibitors such as ibrutinib and Bcl-2 inhibitors such as venetoclax. The final section of this thesis described the results of a phase I clinical trial of the recombinant interleukin-1 (IL-1) receptor antagonist anakinra in CLL patients. Anakinra was found to …
-
CLEC-2 SIGNAL TRANSDUCTION IN PLATELET ACTIVATION
… PI3-Kinase regulates Syk downstream of CLEC-2. Ibrutinib, a Tec family kinase inhibitor, also completely abolished CLEC-2-mediated aggregation and Syk phosphorylation in human and murine platelets. Furthermore, embryos lacking both Btk and Tec exhibited cutaneous edema associated with …